The NASH: Take Action! podcast is a 6-episode limited series designed to fill the educational gaps on screening, diagnosis, and management of NASH identified in the "Preparing for the NASH Epidemic: A Call to Action" health care professional survey and July 10, 2020 conference. The findings of the survey and the conference were published in Gastroenterology. The initiative's steering committee--Fasiha Kanwal, MD, Kenneth Cusi, MD, and Jay Shubrook, DO-- lead engaging conversations in this 6-episodes series.
Sign in to access
After you sign in, please click the "Launch" button on the top of this page to access the course.
Learning Objectives
After completing the educational activity, learners will be able to:
- Understand the prevalence of NAFLD and NASH
- Understand the clinical and economic burdens associated with NAFLD and NASH
Faculty
Fasiha Kanwal, MD
Professor of Medicine
Chief of Gastroenterology & Hepatology
Baylor College of Medicine
Houston, Texas
Jay H. Shubrook, DO
Professor of Medicine, Primary Care
Director of Clinical Research and Diabetes
Touro University
Vallejo, California
Kenneth Cusi, MD
Professor of Medicine
Chief, Endocrinology, Diabetes and Metabolism
The University of Florida
Gainesville, FL
Zobair M. Younossi, MD
Inova Medicine Services
Falls Church, VA
Pricing
|
Member
|
Nonmember
|
| $Free |
$Free |
Accreditation Statement
The AGA Institute is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The AGA Institute designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CME expiration date: Sept. 30, 2022
Disclosure
In accordance with the ACCME’s Standards for Commercial Support of Continuing Medical Education, all faculty and planning partners must disclose any financial relationship(s) or other relationship(s) held within the past 24 months. The AGA Institute implements a mechanism to identify and resolve all conflicts of interest prior to delivering the educational activity to learners.
Fasiha Kanwal has no conflicts reported.
Kenneth Cusi has received research support as principal investigator for the University of Florida from Cirius, Echosens, Inventiva, Novartis, Novo Nordisk, Poxel and Zydus and is a consultant for Allergan, Astra-Zeneca, Axcella, BMS, Boehringer Ingelheim, Coherus, Eli Lilly, Genentech, Gilead, HighTide, Inventiva, Intercept, Ionis, Janssen, Pfizer, Poxel, Prosciento, Madrigal, Novo Nordisk, and Sanofi-Aventis.
Jay H. Shubrook has served as an advisor to Sanofi, Eli Lilly, Novo Nordisk, Bayer, and MannKind.
Zobair Younossi has received research funding from or served as a consultant for Gilead Sciences, Intercept, BMS, Novo Nordisk, Viking, Terns, Siemens, Shionogi, AbbVie, Madrigal, Merck, Abbott, Axcella, and Novartis.
